Nuo Therapeutics, Inc. (AURX) Operating cash flow 2017–2025
Nuo Therapeutics, Inc. (AURX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$864,971FY2025 · since FY2017: -$4.9M → -$864,971
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$864,971 | +61.2% |
| FY2024 | -$2.2M | +29.6% |
| FY2023 | -$3.2M | +14.5% |
| FY2022 | -$3.7M | -2989.6% |
| FY2021 | -$119,955 | -122.9% |
| FY2020 | -$53,821 | +94.2% |
| FY2019 | -$921,674 | -5.4% |
| FY2018 | -$874,388 | +82.2% |
| FY2017 | -$4.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Gross marginAURX Operating incomeAURX Operating marginAURX Free cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →